PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Schering Plough to Present at GTCbio’s 6th Cytokines and Inflammation January 28-29, 2008 - Jianhua Chao, Principal Scientist of Discovery Chemical Research at Schering-Plough will give a presentation entitled “Potent, Orally Active CXCR2-CXCR1 Antagonists as Anti-inflammatory Therapy” at GTCbio’s 6th Cytokines and Inflammation
Schering Plough to Present at GTCbio’s 6th Cytokines and Inflammation January 28-29, 2008

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2008/01/14 - Jianhua Chao, Principal Scientist of Discovery Chemical Research at Schering-Plough will give a presentation entitled “Potent, Orally Active CXCR2-CXCR1 Antagonists as Anti-inflammatory Therapy” at GTCbio’s 6th Cytokines and Inflammation.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Dr. Jianhua Chao is a Principal Scientist of Discovery Chemical Research at Schering-Plough Research Institute. She joined SPRI at the end of 2000 as a Senior Scientist shortly after her completion of Ph.D. study. Over the past seven years, she has been actively involved in a number of discovery research projects ranging across allergy, pulmonary, inflammation, and CNS therapy areas. She has also played a leadership role in a couple of Schering-Plough /Pharmacopeia collaboration projects. In the CXCR2 antagonists program, Dr. Chao and her colleagues have discovered and developed a novel series of receptor antagonists, one of which has been selected as a clinical candidate and being progressed in phase II studies for the treatment of chronic inflammatory disorders. She is an inventor / co-inventor of eighteen patents & patent applications, and an author / coauthor of five scientific publications. Dr. Chao received her Ph.D. degree in Synthetic Organic Chemistry from Florida State University under the direction of Professor Robert A. Holton. Her graduate work focused on the total synthesis of complex natural product Taxol and its 1-deoxy analog. Her strong interest is to apply synthetic capabilities into probing biological targets, design and develop new medications for people and society

The conference also features presentations from other leading organizations such as Amgen, AstraZeneca, Biogen Idec, FDA, Genentech, Merck, NIH, Novo Nordisk, Pfizer, Roche, and many more.

GTCbio’s 6th Cytokines and Inflammation conference will take place on January 28-29, 2008 at the Orlando Metropolitan Resort in Orlando, Florida and will cover Cytokines Signaling and Regulation, Inflammation and Cancer, Technological Developments in Cytokines Biology, Chemokines, and Targeting of Cytokine Receptors

About GTCbio

GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.

GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Schering Plough to Present at GTCbio’s 6th Cytokines and Inflammation January 28-29, 2008

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Rania Hafez 
(626) 256-6405 raniah[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)